
Today on Pharmaceutical Processing
Novartis to expand U.S. manufacturing, R&D footprint with $23B investment
Novartis announced today that it plans to invest $23 billion over five years to expand its U.S.-based infrastructure. The company said its investment aims to ensure all key Novartis medicines for U.S. patients will be made in the U.S. Its financial commitment enables the company to expand on its current pharmaceutical manufacturing, research and technology…BDD Pharma opens new GMP manufacturing plant
BDD announced today that it opened a new 122-square-meter GMP manufacturing facility at BioCity near Glasgow. The company opened its facility after two years of development following a successful inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) last month. A £2 million funding round from existing investors facilitated the development of the state-of-the-art…Sponsored Content See More >
Regulatory See More >

Putting patients first in clinical trials
Clinical trials offer clinicians a unique opportunity to lead advances in medicine, granting access to cutting-edge therapies that address unmet patient needs. They are a cornerstone of clinical practice that enhance patient outcomes, particularly for those with complex or refractory cases who have exhausted standard treatment options. Clinicians understandably prioritize the well-being and interests of…

Confidently navigate the transition from bench to batch

FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths

Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
Learn how to rapidly develop smart and sustainable engineering and production processes See More >

Personalized medicine: advanced technology is saving lives
The concept of a “batch size one” in pharmaceutical manufacturing is closer than ever. There are companies advancing cell therapies in which body cells are used to heal or support the individual patient. These cells are manipulated or edited to change certain biological characteristics before being transferred to the patient. Personalized medicine is truly about…
Facility See More >

J&J breaks ground on $2B manufacturing facility in North Carolina
Johnson & Johnson today announced it broke ground on a $2 billion biologics manufacturing facility in Wilson, N.C., a small portion of the company’s $55 billion U.S. investment initiative over the next four years. The 500,000 ft² facility will expand the company’s capacity to develop and produce advanced therapies for oncology, immunology and neurological diseases.…
Supply Chain See More >

Eli Lilly to more than double U.S. manufacturing investment
Eli Lilly (NYSE:LLY) announced today that it plans to boost domestic pharmaceutical production with four new U.S. manufacturing sites. The company’s investment in capital expansion across therapeutic areas in the U.S. now totals more than $50 billion since 2020. Indianopolis-based Eli Lilly says three of the future U.S. sites will focus on manufacturing active pharmaceutical…
Recalls See More >

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Japanese health authorities searched a Kobayashi Pharmaceutical factory in Japan following reports of five deaths related to dietary supplements, Reuters reports. The plant inspection in western Japan is the second in recent days as health authorities inspected the company’s Osaka facility. In addition to the five reported deaths, there have been more than 100 hospitalizations…